Granite Investment Partners LLC Has $1.48 Million Stock Holdings in Repligen Corporation $RGEN

Granite Investment Partners LLC decreased its position in Repligen Corporation (NASDAQ:RGEN) by 57.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 11,095 shares of the biotechnology company’s stock after selling 14,821 shares during the quarter. Granite Investment Partners LLC’s holdings in Repligen were worth $1,483,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in RGEN. AQR Capital Management LLC bought a new stake in Repligen during the first quarter worth about $262,000. Jones Financial Companies Lllp boosted its holdings in shares of Repligen by 3,850.6% in the 1st quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock worth $814,000 after acquiring an additional 6,238 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Repligen by 16.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock worth $18,067,000 after acquiring an additional 20,375 shares in the last quarter. DekaBank Deutsche Girozentrale grew its position in Repligen by 1.0% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,830 shares of the biotechnology company’s stock worth $961,000 after acquiring an additional 80 shares during the last quarter. Finally, AlphaQuest LLC bought a new position in Repligen in the 2nd quarter valued at $104,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Stock Performance

Shares of Repligen stock opened at $135.40 on Tuesday. The firm has a fifty day moving average of $156.30 and a two-hundred day moving average of $146.71. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.14 and a current ratio of 8.36. The stock has a market capitalization of $7.62 billion, a price-to-earnings ratio of 6,773.39, a PEG ratio of 2.48 and a beta of 1.13. Repligen Corporation has a 52 week low of $102.96 and a 52 week high of $175.77.

Analyst Upgrades and Downgrades

RGEN has been the subject of a number of research reports. Wells Fargo & Company raised their target price on Repligen from $175.00 to $190.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Wall Street Zen raised shares of Repligen from a “hold” rating to a “buy” rating in a report on Saturday, February 7th. Barclays raised their price objective on shares of Repligen from $175.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Canaccord Genuity Group upped their target price on shares of Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a research report on Wednesday, October 29th. Finally, UBS Group raised their price target on shares of Repligen from $190.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 16th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Repligen presently has an average rating of “Moderate Buy” and an average price target of $177.92.

Insider Activity at Repligen

In related news, Director Karen A. Dawes sold 275 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total value of $44,275.00. Following the completion of the sale, the director owned 91,821 shares in the company, valued at approximately $14,783,181. This represents a 0.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 1.20% of the stock is currently owned by company insiders.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.